First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, Al-Batran SE, Mansoor W, Maisey N, Pazo Cid R, Burge M, Perez-Callejo D, Hipkin RW, Mukherjee S, Lei M, Tang H, Suryawanshi S, Kelly RJ, Tebbutt NC.
Hegewisch-Becker S, et al. Among authors: mukherjee s.
J Clin Oncol. 2024 May 9:JCO2301636. doi: 10.1200/JCO.23.01636. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38723227